<DOC>
	<DOCNO>NCT02025725</DOCNO>
	<brief_summary>The purpose study provide confirmation safety efficacy Metoclopramide Nasal Spray compare placebo reduce symptom diabetic gastroparesis adult woman .</brief_summary>
	<brief_title>Multicenter Study Evaluate Efficacy Safety Metoclopramide Nasal Spray Women With Diabetic Gastroparesis</brief_title>
	<detailed_description>Diabetic woman clinical symptom attribute diabetic gastroparesis documentation delay gastric empty meet protocol-specified entry criterion randomize Metoclopramide Nasal Spray 10 mg placebo administer single intranasal spray four ( 4 ) time daily ; 30 minute meal bedtime total four ( 4 ) week .</detailed_description>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<criteria>Non pregnant , non lactate female subject age 18 75 year Willingness ability give write informed consent The ability read , understand speak English Prior diagnosis Type 1 Type 2 diabetes Diagnosis diabetic gastroparesis confirmation delay gastric empty A mean daily gastroparesis symptom score ≥1.4 ≤3.5 prior randomization Subjects childbearing potential must agree use contraception Willingness discontinue current treatment diabetic gastroparesis avoid proscribed ( exclude ) medication , specify protocol , duration study Gastric bypass , gastric banding , gastric pacemaker , post surgical cause gastroparesis disorder know associated abnormal gastrointestinal motility A history allergic adverse response , include , limited , acute dystonic reaction tardive dyskinesia , metoclopramide comparable similar product A history , physical finding suggestive , tardive dyskinesia A history epilepsy currently use unwilling unable stop drug know associate extrapyramidal reaction screen A history allergy ingredient study drug formulation A history organ transplant , chronic pancreatitis , gross malabsorptive syndrome , celiac disease , active inflammatory bowel disease ( IBD ) , symptomatic irritable bowel syndrome ( IBS ) Malignancy ( exception treat squamous cell basal cell carcinoma skin ) currently present , initially diagnose recur within five ( 5 ) year screen Renal dysfunction calculate creatinine clearance ( CrCl ) &lt; 40 mL/min screen Hemoglobin A1c &gt; 11.5 % screening Subjects try conceive , pregnant , lactate</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Gastroparesis</keyword>
	<keyword>Diabetic</keyword>
	<keyword>Delayed gastric empty</keyword>
	<keyword>Gastric stasis</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Bloating</keyword>
	<keyword>Abdominal pain</keyword>
	<keyword>Early satiety</keyword>
	<keyword>Gastropathy</keyword>
</DOC>